"A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma." by S. O'Day

Selected Works of Walter J. Urba, MD, PhD

Article

A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

Journal of Clinical Oncology (2010)

S. O'Day, Cancer Institute
F. S. Hodi, Harvard University
D. F. McDermott, Beth Israel Deaconess Medical Center
R. W. Weber, Dignity Health
J. A. Sosman, Vanderbilt University Medical Center
J. B. Haanen, Cancer Institute
X. Zhu
M. J. Yellin, Medarex
A. Hoos, Bristol-Myers Squibb
W. J. Urba, Providence Portland Medical Center

Link

Disciplines

Publication Date

June 20, 2010

DOI

10.1200/jco.2010.28.18_suppl.4

Citation Information

S. O'Day, F. S. Hodi, D. F. McDermott, R. W. Weber, et al.. "A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma." Journal of Clinical Oncology Vol. 28 (2010) p. 4 - 4
Available at: http://works.bepress.com/walter-urba/170/